Skip to main content

Kevin Pearlstein, MD

Education

  • Undergraduate: Tufts University, Boston, MA
  • Medical School: University of North Carolina School of Medicine, Chapel Hill, NC
  • Internship: University of North Carolina Hospitals, Chapel Hill, NC

Research Interests

Genitourinary cancers, treatment complications and patient quality of life

Publications
(as of 8/5/20)

  • Wang K, Tobillo R, Mavroidis P, Pappafotis R, Pearlstein KA, Moon DH, Mahbooba ZM, Deal AM, Holmes JA, Sheets NC, Kasibhatla MS, Pacholke HD, Royce TJ, Weiner AA, Shen CJ, Zagar TM, Marks LB, Chera BS. Prospective assessment of patient-reported dry eye syndrome after whole brain radiation. Int J Radiat Oncol Biol Phys 2019 Nov 15;105(4):765-772. PMID: 31351194.
  • Pearlstein KA, Basak R, Chen RC. Comparative effectiveness of prostate cancer treatment options: Limitations of retrospective analysis of cancer registry data. Int J Radiat Oncol Biol Phys 2019 Apr 1;103(5):1053-1057. PMID: 30099129.
  • Pearlstein KA, Wang K, Amdur RJ, Shen CJ, Dagan R, Weiss J, Grilley-Olson JE, Zanation A, Hackman TG, Thorp BD, Blumberg JM, Patel S, Sheets N, Weissler MC, Mendenhall WM, Chera BS. Quality of life for patients with favorable-risk HPV-associated oropharyngeal cancer after de-intensified chemoradiotherapy. Int J Radiat Oncol Biol Phys 2019 Mar 1;103(3):646-653. PMID: 30395903.
  • Wang K, Pearlstein KA, Moon DH, Mahbooba ZM, Deal AM, Wang Y, Sutton SR, Motley BB, Judy GD, Holmes JA, Sheets NC, Kasibhatla MS, Pacholke HD, Shen CJ, Zagar TM, Marks LB, Chera BS.  Assessment of risk of xerostomia after whole-brain radiation therapy and association with parotid dose. JAMA Oncol 2019 Feb 1;5(2):221-228  PMID: 30489607.
  • Pearlstein KA, Basak R, Chen RC. Cardiovascular care among cancer survivors in the United States. JNCI Cancer Spectr 2018 Dec 7;2(4):pky049. [Epub]. PMID: 31360872.
  • Cadmus SD, Pearlstein MV, Pearlstein KA, Googe PB, Jolly PS. Paraneoplastic psoriasis in a patient with prostate cancer. JAAD Case Rep. 2018 Feb 23;4(3):220-221. PMID: 29687053.
  • Mavroidis P, Pearlstein KA, Dooley J, Sun J, Saripalli S, Das SK, Wang AZ, Chen RC. Fitting NTCP models to bladder doses and acute urinary symptoms during post-prostatectomy radiotherapy. Radiat Oncol 2018 Feb 2;13(1):17. PMID: 29394931.
  • Wang K, Pearlstein KA, Patchett ND, Deal AM, Mavroidis P, Jensen BC, Lipner MB, Zagar TM, Wang Y, Lee CB, Eblan MJ, Rosenman JG, Socinski MA, Stinchcombe TE, Marks LB. Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer. Radiother Oncol 2017 Nov;125(2):293-300. PMID: 29050957.
  • Ye F, Moon DH, Carpenter WR, Reeve BB, Usinger DS, Green RL, Spearman K, Sheets NC, Pearlstein KA, Lucero AR, Waddle MR, Godley PA, Chen RC. Comparison of patient report and medical records of comorbidities: results from a population-based cohort of patients with prostate cancer. JAMA Oncol 2017 Aug 1;3(8):1035-1042. PMID: 28208186.
  • Diao K, Lobos EA, Yirmibesoglu E, Basak R, Hendrix LH, Barbosa B, Miller SM, Pearlstein KA, Goldin GH, Wang AZ, Chen RC. Patient-reported quality of life during definitive and post-prostatectomy image-guided radiation therapy for prostate cancer. Pract Radiat Oncol 2017 Mar-Apr;7(2):e117-e124. [ePub], PMID: 28274402.
  • Pearlstein KA, Chen RC. Comparing dosimetric, morbidity, quality of life, and cancer control outcomes after 3D conformal, intensity-modulated, and proton radiation therapy for prostate cancer. Semin Radiat Oncol 2013 Jul;23(3):182-190. PMID: 23763884.
  • Kidd JM, Gravel S, Byrnes J, Moreno-Estrada A, Musharoff S, Bryc K, Degenhardt JD, Brisbin A, Sheth V, Chen R, McLaughlin SF, Peckham HE, Omberg L, Bormann Chung CA, Stanley S, Pearlstein K, et al. Population genetic inference from personal genome data: impact of ancestry and admixture on human genomic variation. Am J Human Genet 2012 Oct; 91(4):660-671. PMID: 23040495.
  • Katz LM, Nauriyal V, Nagaraj S, Finch A, Pearlstein K, et al. Infrared imaging of trauma patients for detection of acute compartment syndrome of the leg. Crit Care Med 2008 Jun;36(6):1756-1761. PMID: 18496371.

Meeting Abstracts/Presentations (recent)

  • Mavroidis P, Pearlstein K, Moon D, Sheets N, Kasibhatla M, Shen C, Zagar T, Marks L, Chera B, Das S, Wang K. NTCP modeling and dose-volume correlations of patient reported xerostomia 1 month after whole-brain radiation therapy. American Association of Physicists in Medicine Annual Meeting, San Antonio, TX, July 14-18, 2019. (Poster presentation.)
  • Pearlstein KA, Pryser E, Rankine LJ, Wang K, Mullins B, Holmes JA, Marks LB, Weiner AA. Marginal failures with stereotactic body radiation therapy (SBRT) for early stage lung cancer: Room for improvement? American Society for Radiation Oncology Annual Meeting, San Antonio, TX, October 21-24, 2018. (Poster presentation.)
  • Pearlstein KA, Saripalli S, Basak R, Sun JK, Lobos E, Wang AZ, Chen RC. Obesity and acute urinary and bowel quality of life (QOL) during prostate radiation therapy. American Society for Radiation Oncology Annual Meeting, San Antonio, TX, October 21-24, 2018. (Poster presentation.)
  • Pearlstein KA, Xu C, Deal A, Kaidar-Person O, Chen RC, Jones EL. Racial differences in cervical cancer histology and staging at presentation: a National Cancer Database analysis. American Society for Radiation Oncology Annual Meeting, San Antonio, TX, October 21-24, 2018. (Poster presentation.)
  • Pearlstein KA, Wang K, Amdur RJ, Weiss J, Grilley-Olson J, Zanation A, Hackman T, Thorp B, Blumberg J, Patel S, Sheets NC, Weissler M, Mendenhall WM, Chera BS. Continued improvement in quality of life (QoL) for patients with favorable risk HPV-associated oropharyngeal cancer > 1 year after completing de-intensified chemoradiotherapy.  American Society for Radiation Oncology Annual Meeting, San Antonio, TX, October 21-24, 2018. (Oral presentation.)
  • Pryser E, Pearlstein KA, Rankine L, Wang K, Mullins B, Holmes J, Marks LB, Weiner AA. Dosimetric differences between ray-tracing and Monte Carlo algorithms in early stage lung cancer patients with marginal failures after SBRT. American Association of Physicists in Medicine Annual Meeting, Nashville, TN, July 29 – Aug. 2, 2018. (Poster presentation.)
  • Wang K, Pearlstein KA, Mahbooba Z, Sutton S, et al. Xerostomia is an unrecognized complication of whole brain radiotherapy and may be related to parotid dose: A prospective observational trial. American Society for Radiation Oncology Annual Meeting, San Diego, CA, September 24-27, 2017. (Oral presentation.)
  • Wang K, Pearlstein KA, Patchett ND, Deal A, et al. Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer. American Society for Radiation Oncology Annual Meeting, San Diego, CA, September 24-27, 2017. (Oral presentation.)
  • Pearlstein KA, Dooley J, Saripalli S, Sun J, Das S, Chen R, Mavroidis P. Fitting bladder doses to acute urinary symptoms during post-prostatectomy radiotherapy. American Association of Physicists in Medicine Annual Meeting, Nashville, TN, July 30-August 3, 2017. (Oral presentation.)
  • Pearlstein KA, Basak R, Chen RC. Cardiovascular disease and preventive care among cancer survivors: A population-based study. American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 2-6, 2017. (Poster presentation.)
  • Pearlstein KA, Basak R, Saripalli S, Sun JK, et al. Trajectory of patient-reported urinary and bowel symptom development during modern postprostatectomy radiation therapy. American Society for Radiation Oncology Annual Meeting, Boston, MA, September 25-28, 2016. (Poster presentation.)
Kevin Pearlstein